Monopar Therapeutics (MNPR) Metrics: History & Chart

Monopar Therapeutics Inc.(MNPR)

Biotechnology · Wilmette, IL

$78.20-0.10 (-0.12%)

Delayed quote: Oct 6, 2026, 1:05 PM EDT

About Monopar Therapeutics Inc.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Wilmette, IL

22 employees

www.monopartx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Chandler D. Robinson

View full financials

Third-Party DCF Estimate (FMP)	$7.99
Price Gap vs Third-Party Estimate	-89.64%

7D Total Return	-6.49%
30D Total Return	-33.40%
YTD Total Return	+19.89%
1Y Total Return	-21.23%
3Y Total Return	+2747.03%
5Y Total Return	+235.30%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	+19.89%
2025	+196.82%
2024	+1194.12%
2023	-85.65%
2022	-26.17%
2021	-47.55%
2020

CAGR TTM	-21.14%
CAGR 3Y	+205.27%
CAGR 5Y	+27.38%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

MNPR Valuation Metrics

MNPR Stock Price Metrics

MNPR Dividend Metrics

MNPR Growth Rate Metrics

MNPR Discounted Cash Flow Metrics

MNPR Returns By Period

MNPR Yearly Returns

MNPR Average Annual Returns By Period (CAGR)

MNPR Revenue Metrics

MNPR PE Ratio Metrics

MNPR PS Ratio Metrics

MNPR PB Ratio Metrics

MNPR Price to Free Cash Flow Ratio Metrics

MNPR Debt to Equity Ratio Metrics

MNPR PEG Ratio Metrics

MNPR FCF Yield

MNPR Earnings Yield

MNPR EBITDA Yield

MNPR OCF Yield

MNPR EV/EBIT Ratio Metrics

MNPR EV/EBITDA Ratio Metrics

MNPR EV/Assets Ratio Metrics

MNPR EV/Sales Ratio Metrics

MNPR Current Ratio Metrics

MNPR Quick Ratio Metrics

MNPR ROIC Metrics

MNPR Return on Assets Metrics

MNPR Return on Equity Metrics

MNPR Net Profit Margin Metrics

MNPR Gross Profit Margin Metrics

MNPR Tax Rate Metrics

PS Ratio	N/A
PS Ratio Avg TTM	N/A
PS Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

PB Ratio	5.11
PB Ratio Avg TTM	5.08
PB Ratio Avg 3Y	5.97
Current VS TTM Avg	+0.66%
Current VS 3Y Avg	-14.42%
Current VS 5Y Avg	-31.28%

PFCF Ratio	N/A
PFCF Ratio Avg TTM	N/A
PFCF Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Debt/Equity Ratio	0.00
Debt/Equity Ratio Avg TTM	0.00
Debt/Equity Ratio Avg 3Y	0.00
Current VS TTM Avg	-20.48%
Current VS 3Y Avg	+106.74%
Current VS 5Y Avg	+51.07%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	N/A
FCF Yield Avg TTM	N/A
FCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	4.56
Ev/Assets Ratio Avg TTM	4.50
Ev/Assets Ratio Avg 3Y	4.63
Current VS TTM Avg	+1.26%
Current VS 3Y Avg	-1.51%
Current VS 5Y Avg	-22.16%

Ev/Sales Ratio	N/A
Ev/Sales Ratio Avg TTM	N/A
Ev/Sales Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Current Ratio	33.56
Current Ratio Avg TTM	46.20
Current Ratio Avg 3Y	23.86
Current VS TTM Avg	-27.36%
Current VS 3Y Avg	+40.63%
Current VS 5Y Avg	+74.61%

Quick Ratio	33.56
Quick Ratio Avg TTM	46.20
Quick Ratio Avg 3Y	23.86
Current VS TTM Avg	-27.36%
Current VS 3Y Avg	+40.63%
Current VS 5Y Avg	+74.61%

ROIC	(16.89%)
ROIC Avg 3Y	(74.25%)
ROIC Avg 5Y	(72.46%)
Current VS 3Y Avg	+77.25%
Current VS 5Y Avg	+76.69%
Current VS 10Y Avg	+77.63%

ROA	(13.22%)
ROA Avg TTM	(3.48%)
ROA Avg 3Y	(13.29%)
Current VS TTM Avg	-280.05%
Current VS 3Y Avg	+0.54%
Current VS 5Y Avg	+5.72%

ROE	(13.64%)
ROE Avg TTM	(16.31%)
ROE Avg 3Y	(70.07%)
Current VS TTM Avg	+16.37%
Current VS 3Y Avg	+80.53%
Current VS 5Y Avg	+80.44%

Net Profit Margin	0.00%
Net Profit Margin Avg TTM	0.00%
Net Profit Margin Avg 3Y	0.00%
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Gross Profit Margin	0.00%
Gross Pft Margin Avg TTM	0.00%
Gross Pft Margin Avg 3Y	0.00%
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Tax Rate	0.00%
Tax Rate Avg 3Y	0.00%
Tax Rate Avg 5Y	0.00%
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	-100.00%